Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spermatid maturation protein 1 (SPEM1) is a testis-specific protein encoded by the SPEM1 gene (also known as C17orf83), expressed exclusively in the cytoplasm of developing spermatids during late spermiogenesis[1][3]. It lacks known enzymatic or functional domains and serves as a critical scaffold or adaptor protein, essential for the proper removal of cytoplasm from elongating spermatids. SPEM1 is involved in organizing cytoskeletal and ubiquitin-proteasome system proteins via direct interactions (notably with UBQLN1) at the manchette (a microtubule-based structure) in elongating spermatids[1]. Mice deficient in SPEM1 exhibit complete male infertility due to severe sperm head and cytoplasmic deformities, underscoring its unique and essential role in sperm morphogenesis. There are no reported drugs or established clinical biomarkers targeting SPEM1, and it is not considered a therapeutic target in current medical practice[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spermatid maturation protein 1 (SPEM1).